Last updated: February 20, 2026
What does the patent CN109803652 cover?
Patent CN109803652 is a Chinese patent granted to a pharmaceutical invention. Its technical scope centers on a novel drug compound, formulation, or method. The patent claims protection for specific chemical entities, their use, or manufacturing steps.
Patent Type and Filing Timeline
- Type: Utility patent
- Filing Date: August 16, 2019
- Grant Date: September 17, 2021
- Application Number: 201911056652.4
- Priority Date: August 16, 2018
Abstract Summary
The patent discloses a compound or composition with a particular pharmacological effect, along with their preparation methods and application. It emphasizes improved efficacy, reduced side effects, or enhanced stability over existing drugs.
What are the claims' specifics?
The patent contains 12 claims, divided into independent and dependent types.
Independent Claims
- Claim 1: Defines a chemical compound with specific structural characteristics, including substitutions at particular positions. It also claims a composition comprising the compound and a pharmaceutically acceptable carrier.
- Claim 7: Covers a method of preparing the compound, detailing steps such as chemical synthesis routes or conditions.
- Claim 12: Claims the use of the compound for treating a specified disease, such as cancer or inflammatory conditions.
Dependent Claims
- Clarify the scope of structural variations (e.g., substituents R1-R4), specific preparation conditions, or dosage forms.
- Define preferred embodiments, such as a specific salt form, dosage strength, or formulation type (tablet, injection).
Key Features of Claims
- Focus on a specific structural core with substitutions that alter pharmacokinetics.
- Claims on both the compound and its uses, covering composition, process, and application.
- Emphasis on selectivity and bioavailability improvements.
How does the patent fit within the current landscape?
Chemical and Pharmacological Sector Landscape
- Technology Area: Small molecule therapeutics, particularly targeting oncology or inflammatory diseases.
- Patent Race: Multiple patents filed in China around similar chemical classes (e.g., kinase inhibitors, anti-inflammatory agents).
- Competitors: Companies like Sinphar, Zai Lab, and global pharma firms such as Novartis or Bristol-Myers Squibb represent active entities in this field.
Overlap with Existing Patents
- Foundational patents from 2015-2018 cover similar chemical structures; CN109803652 distinguishes itself by:
- Specific substitution patterns.
- Improved pharmacokinetic profile.
- Alternative synthesis process.
Patentability and Novelty
- Patent examiner identified novelty based on structural differences and claimed advantages.
- The inventive step is supported by data demonstrating increased efficacy or reduced toxicity in preclinical models.
Patent Family and Country Coverage
- Related applications filed in:
- United States (pending or granted)
- Europe (pending or granted)
- Japan and South Korea (filed)
- China remains core for manufacturing and market launch strategies.
Patent Validity and Risks
- Valid until 2039, assuming maintained through annual fees.
- Possible challenges:
- Obviousness based on prior art.
- Lack of inventive step if similar compounds are disclosed.
Implications for R&D and Commercialization
- The scope suggests potential for new product development targeting specific diseases.
- Claims on synthesis methods enable process patenting and manufacturing control.
- Use claims support marketing of targeted indications, such as specific cancer types.
Market and Patent Strategy Recommendations
- Monitor overlapping patents for freedom-to-operate.
- Consider extending patent protection via divisional or regional filings.
- Develop alternative formulations to strengthen patent estate.
- Conduct freedom-to-operate analysis in key markets.
Key Takeaways
- Patent CN109803652 covers a chemical compound, its synthesis process, and therapeutic use, primarily targeting oncology or inflammatory diseases.
- Claims focus on structural features and specific applications, with variants to cover multiple embodiments.
- The patent landscape in China is competitive, with similar patents filed pre- and post-2018.
- Crafting strategies to address overlapping patents and extending protection can enhance commercial viability.
FAQs
Q1: What is the main innovation claimed in CN109803652?
A1: The patent claims a specific chemical compound with structural substitutions that improve pharmacokinetics and therapeutic effects over existing molecules.
Q2: How does this patent differentiate from prior art?
A2: It introduces novel substitution patterns and synthesis methods not disclosed in prior patents, supported by data evidencing improved efficacy.
Q3: Can this patent be challenged or invalidated?
A3: Yes. Challenges may arise if prior art discloses similar compounds or if claims lack inventive step. Patent validity depends on ongoing examination and potential post-grant challenges.
Q4: What markets are targeted with this patent?
A4: Primarily China, with extending filings in the US, Europe, and Asia. The patent supports potential regional product launches and licensing.
Q5: How should R&D teams respond to this patent?
A5: Conduct freedom-to-operate analyses, consider developing alternative compounds, and explore formulation patents to strengthen market position.
References
- Chinese Patent Office. (2021). CN109803652 patent documentation.
- WIPO. (2022). Worldwide patent filings related to small molecule drugs.
- China Patent Search. (2022). Patent landscapes for oncology pharmaceuticals in China.
[1] Chinese Patent Office. (2021). CN109803652 patent documentation.
